These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 14598506)

  • 1. [Innovative technologies in the complex treatment of patients with rheumatoid arthritis].
    Mazurov VI; Lila AM; Raĭmuev KV
    Vestn Ross Akad Med Nauk; 2003; (10):19-24. PubMed ID: 14598506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Extracorporeal therapy of rheumatoid arthritis].
    Aseeva EA; Solov'ev SK; Chiklikchi AS
    Ter Arkh; 2001; 73(6):70-5. PubMed ID: 11521529
    [No Abstract]   [Full Text] [Related]  

  • 3. Effectiveness, tolerability, and safety of subcutaneous methotrexate in early rheumatoid arthritis: A retrospective analysis of real-world data from the St. Gallen cohort.
    Müller RB; von Kempis J; Haile SR; Schiff MH
    Semin Arthritis Rheum; 2015 Aug; 45(1):28-34. PubMed ID: 25895697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Current concepts of pharmacotherapy in rheumatoid arthritis].
    Balabanova RM
    Vestn Ross Akad Med Nauk; 2003; (7):19-23. PubMed ID: 12934465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial.
    Rantalaiho V; Korpela M; Hannonen P; Kautiainen H; Järvenpää S; Leirisalo-Repo M; Hakala M; Puolakka K; Julkunen H; Luosujärvi R; Möttönen T;
    Arthritis Rheum; 2009 May; 60(5):1222-31. PubMed ID: 19404945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis: a five-year randomized followup trial.
    Puolakka K; Kautiainen H; Möttönen T; Hannonen P; Korpela M; Julkunen H; Luukkainen R; Vuori K; Paimela L; Blåfield H; Hakala M; Leirisalo-Repo M
    Arthritis Rheum; 2004 Jan; 50(1):55-62. PubMed ID: 14730599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial.
    Puolakka K; Kautiainen H; Möttönen T; Hannonen P; Korpela M; Hakala M; Järvinen P; Ahonen J; Forsberg S; Leirisalo-Repo M;
    Arthritis Rheum; 2005 Jan; 52(1):36-41. PubMed ID: 15641055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of physicians' adherence to treat-to-target strategy on outcomes in early rheumatoid arthritis in the NEO-RACo trial.
    Kuusalo L; Puolakka K; Kautiainen H; Blåfield H; Eklund KK; Ilva K; Kaipiainen-Seppänen O; Karjalainen A; Korpela M; Valleala H; Leirisalo-Repo M; Rantalaiho V;
    Scand J Rheumatol; 2015; 44(6):449-55. PubMed ID: 26324784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intensive combination treatment regimens, including prednisolone, are effective in treating patients with early rheumatoid arthritis regardless of additional etanercept: 1-year results of the COBRA-light open-label, randomised, non-inferiority trial.
    ter Wee MM; den Uyl D; Boers M; Kerstens P; Nurmohamed M; van Schaardenburg D; Voskuyl AE; Lems WF
    Ann Rheum Dis; 2015 Jun; 74(6):1233-40. PubMed ID: 24818633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparative effectiveness and combined administration of basic drugs in rheumatoid arthritis].
    Noskov SM; Kozlov GS
    Revmatologiia (Mosk); 1991; (1):26-9. PubMed ID: 1676853
    [No Abstract]   [Full Text] [Related]  

  • 11. A phase I/II dose escalation study of intensified cyclophosphamide and autologous blood stem cell rescue in severe, active rheumatoid arthritis.
    Snowden JA; Biggs JC; Milliken ST; Fuller A; Brooks PM
    Arthritis Rheum; 1999 Nov; 42(11):2286-92. PubMed ID: 10555022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of DAS28-CRP remission in patients with rheumatoid arthritis treated with tacrolimus at 6 months by baseline variables.
    Aramaki T; Kawakami A; Iwamoto N; Fujikawa K; Kawashiri SY; Tamai M; Arima K; Kamachi M; Yamasaki S; Nakamura H; Nakashima M; Mizokami A; Furuyama M; Matsuoka N; Ueki Y; Ida H; Origuchi T; Aoyagi K; Eguchi K
    Mod Rheumatol; 2009; 19(6):652-6. PubMed ID: 19787419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tight control and intensified COBRA combination treatment in early rheumatoid arthritis: 90% remission in a pilot trial.
    van Tuyl LH; Lems WF; Voskuyl AE; Kerstens PJ; Garnero P; Dijkmans BA; Boers M
    Ann Rheum Dis; 2008 Nov; 67(11):1574-7. PubMed ID: 18625629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Evidence-based treatment of methotrexate-resistant rheumatoid arthritis. Combinations of conventional disease-modifying antirheumatic agents].
    Schnabel A; Gross WL
    Dtsch Med Wochenschr; 2003 Jan; 128(4):147-9. PubMed ID: 12589584
    [No Abstract]   [Full Text] [Related]  

  • 15. [Synchronous programmed intensive therapy of patients with severe rheumatoid arthritis].
    Solov'ev SK; Aseeva EA; Chiklikchi AS; Nasonova VA
    Ter Arkh; 2002; 74(5):52-7. PubMed ID: 12087908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The combined intensive therapy of rheumatoid arthritis with systemic manifestations].
    Oliunin IuA; Balabanova RM; Solov'ev SK; Chiklikchi AS
    Ter Arkh; 1995; 67(8):59-62. PubMed ID: 7482340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 677C>T and 1298A>C MTHFR polymorphisms affect methotrexate treatment outcome in rheumatoid arthritis.
    Kurzawski M; Pawlik A; Safranow K; Herczynska M; Drozdzik M
    Pharmacogenomics; 2007 Nov; 8(11):1551-9. PubMed ID: 18034620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A population model of early rheumatoid arthritis disease activity during treatment with methotrexate, sulfasalazine and hydroxychloroquine.
    Wojciechowski J; Wiese MD; Proudman SM; Foster DJ; Upton RN
    Br J Clin Pharmacol; 2015 May; 79(5):777-88. PubMed ID: 25394211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infliximab for 6 months added on combination therapy in early rheumatoid arthritis: 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study).
    Leirisalo-Repo M; Kautiainen H; Laasonen L; Korpela M; Kauppi MJ; Kaipiainen-Seppänen O; Luosujärvi R; Luukkainen R; Karjalainen A; Blåfield H; Uutela T; Ilva K; Julkunen HA; Paimela L; Puolakka K; Moilanen E; Hannonen PJ; Möttönen T;
    Ann Rheum Dis; 2013 Jun; 72(6):851-7. PubMed ID: 22753402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Indirect and total costs of early rheumatoid arthritis: a randomized comparison of combined step-down prednisolone, methotrexate, and sulfasalazine with sulfasalazine alone.
    Korthals-de Bos I; Van Tulder M; Boers M; Verhoeven AC; Adèr HJ; Bibo J; Boonen A; Van Der Linden S
    J Rheumatol; 2004 Sep; 31(9):1709-16. PubMed ID: 15338488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.